Hynden Walch's social media journey is far from over. She continues to create content, engage with her fans, and explore new opportunities. Her future plans include expanding her brand, collaborating ...

Kathleen Walch is a thought leader, dynamic presenter and keynote speaker covering AI, ML, and big data use cases, applications, and best practices. She has been writing for Forbes since 2018.

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments ...

Carolyn Johnson is a science reporter. She previously covered the business of health, the pharmaceutical industry and the affordability of health care to consumers. Before coming to the Post ...

Johnson & Johnson (JNJ) beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highlighted in the ...

The president plans to highlight his proposed name change mid-route on Air Force One.

Bryan Johnson, a tech entrepreneur, has stopped using rapamycin, a drug not approved for anti-aging by the FDA, following concerns it may have aged him and caused infections. Johnson experienced ...

Supported by operational growth of 6.7%, Johnson & Johnson (JNJ, Financials) reported a 5.3% rise in fourth-quarter revenues to $22.5 billion. With operational growth of 5.9% except for COVID-19 ...

Gabby Jones / Bloomberg / Getty Images Johnson & Johnson is scheduled to report fourth-quarter earnings Wednesday morning, with analysts expecting sales and profits to grow year-over-year.